Revenue: As of FY2026 Q1, the actual value is USD 0.EPS: As of FY2026 Q1, the actual value is USD -6.95.EBIT: As of FY2026 Q1, the actual value is USD -5.634 M.Ernexa Therapeutics Inc. operates within a single reportable operating segment, focusing on the research and development of cellular therapies .<h4>Operational Metrics</h4><ul><li>Net Loss: Ernexa Therapeutics Inc. reported a net loss of - $5,506 thousand for the three months ended March 31, 2026, compared to - $8,202 thousand for the same period in 2025 .</li><li>Total Operating Expenses: Total operating expenses increased by $2,860 thousand, from $2,730 thousand in 2025 to $5,590 thousand in 2026 .<ul><li>Research and Development (R&amp;D) Expenses: R&amp;D expenses increased by $606 thousand, from $1,309 thousand in 2025 to $1,915 thousand in 2026 . This increase was primarily driven by increased study fees related to ERNA-101 ($1,267 thousand in 2026 vs. $352 thousand in 2025) and higher payroll from increased R&amp;D headcount ($236 thousand in 2026 vs. $112 thousand in 2025), partially offset by a reduction in MSA/license fees ($69 thousand in 2026 vs. $637 thousand in 2025) .</li><li>General and Administrative (G&amp;A) Expenses: G&amp;A expenses increased by $210 thousand, from $1,421 thousand in 2025 to $1,631 thousand in 2026 . This was mainly due to increases in payroll related to accrued bonuses ($802 thousand in 2026 vs. $394 thousand in 2025) and professional fees for legal matters, partially offset by a reduction in stock-based compensation ($296 thousand in 2026 vs. $486 thousand in 2025) and other expenses .</li><li>Impairment of Goodwill: The company recognized a $2,044 thousand impairment charge of goodwill in 2026, with no similar expense in 2025 .</li></ul></li><li>Loss from Operations: The loss from operations increased to - $5,590 thousand in 2026 from - $2,730 thousand in 2025 .</li><li>Other Income (Expense), net: Total other income (expense), net, was $44 thousand in 2026 compared to - $5,464 thousand in 2025, primarily due to a - $5,335 thousand forward sales contract expense recognized in 2025 that did not recur in 2026 .</li><li>Interest Income, net: Net interest income increased to $44 thousand in 2026 from $5 thousand in 2025, attributed to an increase in cash in interest-bearing accounts .</li></ul><h4>Cash Flow</h4><ul><li>Net Cash Used in Operating Activities: Net cash used in operating activities increased to - $2,264 thousand in 2026 from - $2,065 thousand in 2025 .</li><li>Net Cash Used in Investing Activities: Net cash used in investing activities was - $2 thousand in 2026 for property and equipment purchases, with no such purchases in 2025 .</li><li>Net Cash Provided by Financing Activities: Net cash provided by financing activities significantly increased to $9,559 thousand in 2026, primarily from $9.5 million in net proceeds from a public offering, compared to $2,254 thousand in 2025 which included proceeds from promissory notes .</li><li>Cash Balance: As of March 31, 2026, the cash balance was $9,177 thousand, up from $1,884 thousand as of December 31, 2025 . As of April 30, 2026, the cash balance was approximately $8.3 million .</li></ul><h4>Future Outlook and Strategy</h4>Ernexa Therapeutics Inc. plans to complete IND-enabling studies and submit an Investigational New Drug (IND) application in 2026 for ERNA-101, with a Phase I clinical trial anticipated in the second half of 2026 for platinum-resistant ovarian cancer . The company is also investigating ERNA-201 for autoimmune disorders and is actively seeking partnerships to co-develop or out-license therapeutic assets, alongside applying for research grants to raise non-dilutive capital . Ernexa Therapeutics Inc. expects its At-the-Market (ATM) program to provide access to capital to cover shortfalls in cash resources over the next twelve months .

Ernexa Therapeutics | 10-Q: FY2026 Q1 Revenue: USD 0